Samsung Biologics enters its second month of an unprecedented labor stoppage with management offering 6.2% while the union pursues 20% of operating profit — a benchmark its semiconductor affiliate just reset at 12%.
Samsung Biologics (KRX: 207940), Korea's largest contract drug manufacturer (CDMO), has not yet matched the wage settlement its memory-chip affiliate concluded on May 20 — leaving the unit in protracted talks with its first-ever striking union just as the broader Samsung group faces a redrawn template for sharing operating profits with employees.
On May 19, the Jungbu Regional Employment and Labor Office — the field branch of MOEL (Korea's Ministry of Employment and Labor) — brokered a tripartite meeting between Samsung Biologics management, the union, and government mediators, according to Electronic Times (etnews). A closed follow-up scheduled for May 20 did not yield additional negotiations, with both sides exchanging revised proposals but failing to narrow the gap.
The contrast is sharp. One day later, Samsung Electronics, Korea's flagship memory chipmaker, confirmed a tentative deal that, per Chosun Biz citing the agreement framework, allocates 12% of its semiconductor (Device Solutions) division profits to a worker bonus pool — 10.5% to a capless special bonus and 1.5% to the existing performance incentive. The deal was reached the night before its 47,000-member union had planned to begin a strike running May 21 through June 7, CNBC reported, with a ratification vote scheduled for May 22 to May 27.
How wide is the Biologics gap
The Biologics union is asking for materially more than its electronics affiliate just accepted. Per the Korea Herald, its demands consist of a 14% combined increase in base and performance pay, a one-off cash incentive of ₩30 million (~$20,400) per worker, and bonuses equal to 20% of annual operating profit. Management has tabled a 6.2% combined raise.
Applied to FY2025 operating profit of ₩2,069.2 billion ($1.51 billion) — up 56.6% year-on-year, per the company's January 21 earnings release — a 20% profit-share would convert to roughly ₩413.8 billion ($302 million) annually for the bonus pool alone, before the cash incentive. That figure is approximately 78% of the company's Q4 2025 operating profit of ₩528.3 billion ($386 million) reported in the same release.
Strike damage already on the books
Even before the latest impasse, the union's first-ever walkout — running May 1 through May 5 — produced measurable disruption. Fierce Pharma reported that Samsung Biologics estimated about ₩150 billion ($102 million) in financial impact from the action. Management had projected that losses from a sustained full-scale strike could exceed ₩640 billion ($467 million), roughly half of its Q1 2026 sales of ₩1.26 trillion ($920 million), per the Korea Herald.
The walkout is the first since the company's 2011 founding, the Seoul Economic Daily reported; about 2,800 of the union's roughly 4,000 members — out of a 5,455-person workforce — ultimately participated, per the Korea Herald. A court order partially restricted action across three of nine production phases, per the Korea Herald, which mitigated but did not eliminate the operational risk that biological raw materials in a halted line may have to be discarded mid-run.
A redrawn template across Korea Inc.
The 12% Samsung Electronics figure resets the negotiating floor in a way Biologics management cannot easily ignore. Chosun Biz, citing the demand schedule, notes the cascade now under way: SK Hynix — Korea's second-largest memory chipmaker — previously agreed to a 10% operating-profit bonus structure; Samsung Electronics has now agreed to 12%; the Hyundai Motor (Korea's largest automaker) union is seeking 30% of net income; the unions at Kia (Hyundai's affiliate automaker), HD Hyundai Heavy Industries (Korea's largest shipbuilder), and LG Uplus (Korea's #3 telecom carrier) are pursuing 30% of operating profit; Samsung Biologics is asking for 20%.
Korea's three principal business lobbies — the Korea Chamber of Commerce and Industry (KCCI), the Federation of Korean Industries (FKI), and the Korea Enterprises Federation (KEF) — issued statements on May 21 welcoming the Samsung Electronics deal while warning that formulaic profit-share demands risk amplifying business-cycle uncertainty, per Chosun Biz. A separate shareholder group, the Korea Shareholders' Movement Headquarters, said the same day it would seek injunctions and derivative suits against Samsung Electronics directors who ratify the 12% framework, citing the revised Commercial Act provision extending directors' fiduciary duties to shareholders — though Chosun Biz quoted labor and corporate attorneys saying the suits face high evidentiary hurdles under the business judgment rule.
What to watch
The Samsung Electronics ratification vote running May 22 through May 27, per CNBC, is the operational benchmark the Biologics union can cite if it holds. Samsung Biologics has guided 15–20% revenue growth for 2026 — excluding any contribution from its announced U.S. facility acquisition, per the January 21 earnings release — making a prolonged production interruption costlier in absolute terms than the 2025 baseline implies. The next scheduled mediation session, and any move by either side off the 6.2%/20% gap, will be the data point that confirms or refutes the working assumption that Electronics' 12% has reset the floor.
This article is for informational purposes only and does not constitute investment advice.
Sources
- Electronic Times (etnews) — Samsung Bio negotiations under government mediation, May 21, 2026-05-21
- Chosun Biz — Samsung Electronics deal aftershocks — subcontractors, farmers, shareholders, May 21, 2026-05-21
- Korea Herald — Samsung Biologics union demands and strike particulars, 2026-05-08
- Korea Herald — Samsung Biologics court order and strike scope, 2026-05-04
- Seoul Economic Daily — Samsung Biologics union launches first-ever strike May 1, 2026-04-30
- Fierce Pharma — Samsung Biologics estimates ~$102M impact from union strike, 2026-05-18
- CNBC — Samsung Electronics union strike suspended after wage deal, 2026-05-21
- Samsung Biologics IR — Q4 and FY2025 financial results — operating profit ₩2,069.2B, 2026-01-21
